Journal article

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease

Andrew Schmidt, Angelyn Anton, Julia Shapiro, Shirley Wong, Arun Azad, Edmond Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony M Joshua, David Pook, Peter Gibbs, Ben Tran, Andrew Weickhardt

Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2020


AIM: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients deriving benefit from the addition of docetaxel to androgen deprivation therapy (D-ADT). This study sought to define the therapy used and associated activity following D-ADT. METHODS: Retrospective analysis of patients with mHSPC treated with one or more cycles of D-ADT who were identified from a prospectively maintained multisite prostate cancer database of patients treated in a community or academic center setting in Australia. The primary endpoint of this study was first-line time to treatment failure (1L TTF) for subsequent treatment of metastatic Castrate Resis..

View full abstract